JB

Joshua Brumm

Chief Executive Officer

Crescent Biopharma

Therapeutic Areas

Crescent Biopharma Pipeline

DrugIndicationPhase
Undisclosed Bispecific Program (e.g., PD-1 x VEGF)Solid TumorsPhase 1
Undisclosed ADC ProgramSolid TumorsPreclinical